Drug intelligence / Profile preview

BoviPhage

Development stage: Preclinical
Lead developer: Cytophage Technologies

Overview

BoviPhage is a bacteriophage-based veterinary product developed by Cytophage Technologies for the treatment and prevention of bovine mastitis. As a phage therapy, it utilizes viruses that specifically infect and lyse pathogenic bacteria responsible for udder infections in dairy cattle. This approach provides a targeted antimicrobial effect, offering an alternative to conventional antibiotics and helping to mitigate the issues of antimicrobial resistance (AMR) and antibiotic residues in the dairy industry.

Brand names: BoviPhage

Targets

F5 (Coagulation Factor V)

Beyond the preview

Go deeper on BoviPhage.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BoviPhage.

Explore the full profile